Acetylenic analog of arachidonate that acts like aspirin on platelets.
Development of irreversible platelet aggregation and the accompanying release of platelet-bound serotonin and production of prostaglandins is suppressed by 5,8,11,14-eicosatetraynoic acid (TYA). These findings may be explained by an ability of TYA to inhibit the enzymatic conversion of arachidonate to a newly recognized factor, labile aggregation-stimulating substance, which induces platelet aggregation, and to prostaglandins E(2) and F(2alpha).
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors; D001095:Arachidonic Acids / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology*; D001792:Blood Platelets / Q000378:metabolism*; D002250:Carbon Radioisotopes; D003094:Collagen / Q000037:antagonists & inhibitors; D003864:Depression, Chemical; D004837:Epinephrine / Q000037:antagonists & inhibitors; D005231:Fatty Acids, Unsaturated / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D010973:Platelet Adhesiveness / Q000187:drug effects*; D011453:Prostaglandins / Q000096:biosynthesis*; D012701:Serotonin / Q000378:metabolism; D013917:Thrombin / Q000037:antagonists & inhibitors
D001095:Arachidonic Acids; D002250:Carbon Radioisotopes; D005231:Fatty Acids, Unsaturated; D011453:Prostaglandins; D012701:Serotonin; D000244:Adenosine Diphosphate; D003094:Collagen; D013917:Thrombin; D001241:Aspirin; D004837:Epinephrine